The product is licensed by clients such as aging-in-place facilities, wellness-focused businesses, care management organizations, health systems, and employee benefits leaders.
Enterprises can deploy the solution for use with a general managed population or an at-risk population, such as seniors, postoperative patients, those with health conditions, or new mothers.
Through an easy-to-use dashboard, an enterprise can survey, message and educate its population while the connected mobile App empowers and engages patients/employees and their families through alerts, journals, reminders, surveys, instant messaging, and tailored content.
Research by the American Heart Association indicates that incorporating family support and providing easy-to-read educational material to patients and their caregivers enhance medication adherence.
Another element of the App is targeted educational assistance (TEA), a health condition education content that is auto-delivered to the App from sources such as the National Library of Medicine.
The App also includes features to increase medication adherence. The dashboard also contains population health analytics tools tailored to the needs of the enterprise.
ICMed is a mobile patient & family engagement solution.
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets
Pharming secures Japan approval for Joenja in rare immune disorder treatment
BioArctic and Eisai present new lecanemab and exidavnemab data at AD/PD 2026
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform